ES2558960T3 - Composición nutricional para la prevención de infecciones - Google Patents
Composición nutricional para la prevención de infecciones Download PDFInfo
- Publication number
- ES2558960T3 ES2558960T3 ES09762710.3T ES09762710T ES2558960T3 ES 2558960 T3 ES2558960 T3 ES 2558960T3 ES 09762710 T ES09762710 T ES 09762710T ES 2558960 T3 ES2558960 T3 ES 2558960T3
- Authority
- ES
- Spain
- Prior art keywords
- oligosaccharides
- milk
- bifidobacteria
- mixture
- incubated mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title abstract description 8
- 208000015181 infectious disease Diseases 0.000 title description 5
- 230000002265 prevention Effects 0.000 title description 2
- 235000016709 nutrition Nutrition 0.000 title 1
- 229920001542 oligosaccharide Polymers 0.000 abstract description 12
- 102000007544 Whey Proteins Human genes 0.000 abstract description 4
- 108010046377 Whey Proteins Proteins 0.000 abstract description 4
- 150000002482 oligosaccharides Chemical class 0.000 abstract description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract description 3
- 239000008101 lactose Substances 0.000 abstract description 3
- 235000021119 whey protein Nutrition 0.000 abstract description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 abstract description 2
- 239000005018 casein Substances 0.000 abstract description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 abstract description 2
- 235000021240 caseins Nutrition 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- 241000186000 Bifidobacterium Species 0.000 abstract 3
- 235000013336 milk Nutrition 0.000 abstract 2
- 239000008267 milk Substances 0.000 abstract 2
- 210000004080 milk Anatomy 0.000 abstract 2
- 239000000758 substrate Substances 0.000 abstract 2
- 102000014171 Milk Proteins Human genes 0.000 abstract 1
- 108010011756 Milk Proteins Proteins 0.000 abstract 1
- 239000005862 Whey Substances 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 238000005119 centrifugation Methods 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 abstract 1
- 150000003271 galactooligosaccharides Chemical class 0.000 abstract 1
- 238000010438 heat treatment Methods 0.000 abstract 1
- 150000003272 mannan oligosaccharides Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 235000021239 milk protein Nutrition 0.000 abstract 1
- 235000021140 nondigestible carbohydrates Nutrition 0.000 abstract 1
- 239000003531 protein hydrolysate Substances 0.000 abstract 1
- 206010070545 Bacterial translocation Diseases 0.000 description 9
- 230000007375 bacterial translocation Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000002054 inoculum Substances 0.000 description 4
- 241000031670 Saccharopolyspora thermophila Species 0.000 description 3
- 235000013350 formula milk Nutrition 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 235000019871 vegetable fat Nutrition 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 206010039438 Salmonella Infections Diseases 0.000 description 1
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000021004 dietary regimen Nutrition 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229920000157 polyfructose Polymers 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 206010039447 salmonellosis Diseases 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/017—Hydrolysed proteins; Derivatives thereof from animals from blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Pediatric Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Dairy Products (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Proceso para la producción de una preparación que comprende los pasos de: a: incubar un sustrato acuoso con bifidobacterias, donde el sustrato comprende al menos un elemento seleccionado del grupo consistente en leche, proteína de la leche, suero de leche, proteína de suero de leche, hidrolizado proteico de suero de leche, hidrolizado de caseína, y lactosa para obtener una mezcla incubada; b: inactivar las bifidobacterias por calentamiento de la mezcla incubada y/o eliminar células de bifidobacterias de la mezcla incubada mediante centrifugado y/o filtración; c: combinar una composición que comprende la mezcla obtenida en el paso a u obtenida en el paso b, preferiblemente obtenida en el paso b con al menos dos carbohidratos no digeribles diferentes, donde al menos uno, preferiblemente dos, es/son seleccionado(s) del grupo consistente en fructo-oligosacáridos, galacto-oligosacáridos, gluco-oligosacáridos, arabino-oligosacáridos, manano- oligosacáridos, xilooligosacáridos, fuco-oligosacáridos, arabinogalacto- oligosacáridos, glucomanno-oligosacáridos, galactomanno-oligosacáridos, rafinosa, lactosacarosa, ácido siálico que comprende oligosacáridos y oligosacáridos de ácido urónico.
Description
[0098] Posteriormente se introdujo una infección de Salmonella por alimentación forzada oral de Salmonella enteritidis LMG22715, 2x105 UFC/ratón en tampón de 0,2 ml. Después 6 días de infección los ratones fueron sacrificados y la translocación bacteriana a los órganos fue medida
5 como uno de los principales parámetros. Durante el periodo de infección el régimen de dieta no fue cambiado. También se midió la puntuación de enfermedad. La puntuación de enfermedad es una indicación de enfermedad basada en la pérdida de peso, reactividad y grado de alerta, y estado del pelaje.
10 Resultados
[0099] La ingesta de alimentos y el crecimiento fue comparable en todos grupos en el periodo antes de que la infección fuera introducida.
15 [0100] La Tabla 2 muestra los resultados en la salud general, y translocación bacteriana (BT) a órganos diferentes. La puntuación de enfermedad y la translocación bacteriana al hígado y bazo fue inferior en el grupo 2 que en el grupo 1 debido a la presencia adicional de GF. El log de BT al hígado, bazo, pulmón y riñón fue inferior en 2 que en 1 debido a GF.
20 Tabla 2: Puntuación de enfermedad y translocación bacteriana (número de logaritmo de UFC por g de tejido en el logaritmo) en el día 34.
- Dieta
- Puntuación enfermedad Log BT hígado Log BT bazo Log BT riñón Log BT pulmón
- 1
- 4.85 3.80 3.70 2.56 2.75
- 2
- 3.65 2.37 2.40 1.89 2.05
- 3
- 4.93 3.85 4.20 3.15 320
[0101] Los resultados de este experimento son una indicación de que la presente invención puede ser usada 25 ventajosamente para el tratamiento y/o la prevención de infecciones, y/o translocación bacteriana y/o para la mejora de la función de la barrera intestinal.
Ejemplo 2: fórmula de leche infantil
30 [0102] Leche de la vaca desnatada pasteurizada fue concentrada por evaporación hasta aproximadamente 43 % en peso de sustancia seca en base al peso de la leche de vaca desnatada. El concentrado fue enfriado a aproximadamente 37 °C, fue luego inoculado con aproximadamente 10 % (v/p) de cultivo de B. breve CNCM I-2219 que comprende 3x109 UFC por ml. Este inóculo se preparó como se conoce en la técnica. El pH inicial estaba entre 6-7,1.
35 Después de la incubación durante 8 h a 37°C, en un tanque con agitación periódica durante 10 minutos cada 2 horas, el pH permaneció entre 6- 7,1 y la población de B. breve fue aproximadamente 106 bacterias/ml (paso (a)).
[0103] Un inóculo precalentado fue preparado a partir de cultivo S. thermophilus CNCM I-1620 manteniendo un inóculo congelado durante aproximadamente 7 h a alrededor de 40 °C.
40 Una solución de lactosa pasteurizada (entre 350 y 450 g/l) fue enfriada a aproximadamente 45 y 55 °C, y luego inoculada con aproximadamente 10 % (v/p) de un inóculo de S. thermophilus CNCM I-1620 precalentado que comprendía aproximadamente 3 x109 UFC por ml. El inicial pH fue de alrededor de pH 6. Después de la incubación durante aproximadamente 7 h a alrededor de 50°C, en un tanque con agitación periódica
45 durante 10 minutos cada 2 horas, el pH fue mantenido constante entre 6-8 y la población de S. thermophilus fue aproximadamente de 106 bacterias/ml (paso (d)).
[0104] Ambas preparaciones incubadas, leche desnatada, grasa vegetal, malto, trans-galacto oligosacáridos y oligosacáridos de fructo-oligosacáridos, y otros ingredientes bien conocidos para fórmulas de leche infantil (tales 50 como vitaminas, minerales, oligoelementos) fueron mezclados (paso c, f). La mezcla fue pasteurizada (paso b, e) y posteriormente secada por atomización.
[0105] Composición final de la fórmula infantil que comprende por 100 ml:
55 - 68 kcal
16
- -
- 1,45 g de proteína (caseína y proteína de suero de leche de leche; parcialmente hidrolizada)
- -
- 8,6 g de carbohidratos digeribles (principalmente lactosa y maltodextrina)
- -
- 3,1 g de grasas (principalmente grasas vegetales)
- -
- 0.8 g de galactoligosaccharides (fuente VivinalGOS) y polifructosa (fuente RaftilinHP)
- -
- Oligoelementos, minerales, vitaminas y otros micronutrientes (taurina, colina, inositol, nucleótidos, carnitina) como se conocen en la técnica.
17
Claims (1)
-
imagen1 imagen2
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| WOPCT/NL2008/050375 | 2008-06-13 | ||
| PCT/NL2008/050375 WO2009151315A1 (en) | 2008-06-13 | 2008-06-13 | Nutritional composition for infants delivered via caesarean section |
| EP08168054 | 2008-10-31 | ||
| EP08168054 | 2008-10-31 | ||
| PCT/NL2009/050330 WO2009151329A1 (en) | 2008-06-13 | 2009-06-12 | Nutrition for prevention of infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2558960T3 true ES2558960T3 (es) | 2016-02-09 |
Family
ID=40935729
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES09762710.3T Active ES2558960T3 (es) | 2008-06-13 | 2009-06-12 | Composición nutricional para la prevención de infecciones |
| ES09762711.1T Active ES2656776T3 (es) | 2008-06-13 | 2009-06-12 | Composición nutricional para bebés nacidos por cesárea |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES09762711.1T Active ES2656776T3 (es) | 2008-06-13 | 2009-06-12 | Composición nutricional para bebés nacidos por cesárea |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US20110182934A1 (es) |
| EP (4) | EP2293677B1 (es) |
| CN (3) | CN102065867A (es) |
| AR (3) | AR072142A1 (es) |
| BR (1) | BRPI0915149B1 (es) |
| DK (1) | DK2285387T3 (es) |
| ES (2) | ES2558960T3 (es) |
| HU (1) | HUE028390T2 (es) |
| PL (2) | PL2285387T3 (es) |
| PT (1) | PT2285387E (es) |
| RU (2) | RU2543634C2 (es) |
| SI (1) | SI2285387T1 (es) |
| WO (3) | WO2009151329A1 (es) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009072889A1 (en) | 2007-12-07 | 2009-06-11 | N.V. Nutricia | Bifidobacterium for dust mite allergy |
| CN102065867A (zh) | 2008-06-13 | 2011-05-18 | N.V.努特里奇亚 | 预防感染的营养物 |
| CA2761444C (en) | 2009-05-11 | 2018-04-24 | Nestec S.A. | Lactobacillus johnsonii la1 ncc533 (cncm i-1225) and immune disorders |
| WO2011121379A1 (en) * | 2010-03-30 | 2011-10-06 | Assistance Publique - Hopitaux De Paris | Use of bifidobacteria for preventing allergy in breastfed infants |
| WO2011148221A1 (en) * | 2010-05-28 | 2011-12-01 | Compagnie Gervais Danone | Lactic acid bacteria for maturation of the enteric nervous system in infants |
| EP3097791B1 (en) * | 2010-06-04 | 2018-05-16 | N.V. Nutricia | Non-digestible oligosaccharides for oral induction of tolerance against dietary proteins |
| WO2011150949A1 (en) * | 2010-06-04 | 2011-12-08 | N.V. Nutricia | Non-digestible oligosaccharides for oral induction of tolerance against dietary proteins |
| KR101757504B1 (ko) * | 2010-06-28 | 2017-07-12 | 가부시키가이샤 야쿠르트 혼샤 | 경구용 피부 성상 개선제 |
| WO2012057636A1 (en) * | 2010-10-27 | 2012-05-03 | Fonterra Corporate Research And Development Limited | Modulation of th1 and th2 immune response by lactic acid whey |
| EP2449891A1 (en) * | 2010-11-05 | 2012-05-09 | Nestec S.A. | Drinking yoghurt preparations containing non-replicating probiotic micro-organisms |
| AU2011328041A1 (en) * | 2010-11-11 | 2013-05-23 | Nestec S.A. | Spoonable yogurt preparations containing non-replicating probiotic micro-organisms |
| RU2593716C2 (ru) * | 2010-11-11 | 2016-08-10 | Нестек С.А. | Замороженные кондитерские изделия, содержащие пробиотические микроорганизмы |
| EP2465508A1 (en) * | 2010-11-23 | 2012-06-20 | Nestec S.A. | Composition comprising hydrolysed proteins and oligosaccharides for treating skin diseases |
| WO2012078030A1 (en) * | 2010-12-06 | 2012-06-14 | N.V. Nutricia | Fermented infant formula |
| EP2520181A1 (en) * | 2011-05-02 | 2012-11-07 | N.V. Nutricia | Fermented infant formula |
| BR112013013777B1 (pt) * | 2010-12-06 | 2019-10-29 | Nutricia Nv | método não terapêutico e composição nutricional para bebês |
| WO2012078032A1 (en) | 2010-12-10 | 2012-06-14 | N.V. Nutricia | Early stimulation of taste and/or flavour acceptance |
| EP3335576A1 (en) * | 2010-12-31 | 2018-06-20 | Abbott Laboratories | Human milk oligosaccharides to promote growth of beneficial bacteria |
| PL2481299T3 (pl) | 2011-01-31 | 2017-09-29 | Synformulas Gmbh | Szczepy bifidobacterium bifidum do stosowania w chorobach przewodu pokarmowego |
| MY182335A (en) | 2011-07-22 | 2021-01-19 | Abbott Lab | Galactooligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract |
| WO2013053073A1 (zh) * | 2011-10-10 | 2013-04-18 | Huang Daiyong | 一种基于甘露寡糖的胃肠道健康因子组合物 |
| WO2013187755A1 (en) * | 2012-06-14 | 2013-12-19 | N.V. Nutricia | Fermented infant formula with non digestible oligosaccharides |
| US9974816B2 (en) * | 2012-11-02 | 2018-05-22 | N.V. Nutricia | Synbiotics combination for brain improvement |
| CA3012383C (en) | 2013-02-28 | 2021-03-02 | Teewinot Technologies Limited | Biosynthesis of cannabinoids |
| US9352020B2 (en) * | 2013-03-15 | 2016-05-31 | Mead Johnson Nutrition Company | Reducing proinflammatory response |
| US20140271978A1 (en) * | 2013-03-15 | 2014-09-18 | Mead Johnson Nutrition Company | Low-buffer nutritional compositions and uses thereof |
| WO2014168474A1 (en) * | 2013-04-08 | 2014-10-16 | N.V. Nutricia | Fermented nutritional composition with thiol protease inhibitor |
| WO2014200334A1 (en) * | 2013-06-14 | 2014-12-18 | N.V. Nutricia | Synbiotic composition for treatment of infections in allergic patients |
| CN104413334A (zh) * | 2013-08-30 | 2015-03-18 | 深圳华大基因科技有限公司 | 可食用组合物及其制备方法和用途 |
| EP2857410A1 (en) | 2013-10-04 | 2015-04-08 | Jennewein Biotechnologie GmbH | Process for purification of 2´-fucosyllactose using simulated moving bed chromatography |
| AU2014350144B2 (en) | 2013-11-15 | 2019-11-21 | Société des Produits Nestlé S.A. | Compositions for use in the prevention or treatment of URT infections in infants or young children at risk |
| EP3082473A2 (en) * | 2013-12-19 | 2016-10-26 | Nestec S.A. | Nutritional composition to reduce metabolic stress in infants |
| CA2959283A1 (en) | 2014-08-25 | 2016-03-03 | Full Spectrum Laboratories Limited | Apparatus and methods for the simultaneous production of cannabinoid compounds |
| WO2016183535A1 (en) | 2015-05-14 | 2016-11-17 | University Of Puerto Rico | Methods for restoring microbiota of newborns |
| WO2017043962A1 (en) * | 2015-09-11 | 2017-03-16 | N.V. Nutricia | Method for stimulating microbiota health after non-natural birth |
| EP3150257A1 (en) * | 2015-09-30 | 2017-04-05 | Buga, Doris | A method for producing a composition for strengthening the immune system |
| CN105341938B (zh) * | 2015-10-10 | 2018-06-26 | 北京康比特体育科技股份有限公司 | 一种降低大强度运动后呼吸道感染率的保健食品 |
| WO2017117142A1 (en) | 2015-12-28 | 2017-07-06 | New York University | Device and method of restoring microbiota of newborns |
| WO2017114901A1 (en) * | 2015-12-29 | 2017-07-06 | N.V. Nutricia | Nutritional formula with non-digestible oligosaccharides and non-replicating lactic acid producing bacteria |
| BR112018013501B1 (pt) * | 2015-12-29 | 2022-12-20 | N.V. Nutricia | Uso de um ingrediente fermentado e oligossacarídeo não digerível |
| WO2017194607A1 (en) | 2016-05-10 | 2017-11-16 | N.V. Nutricia | Fermented infant formula |
| CN109475165A (zh) | 2016-05-10 | 2019-03-15 | N·V·努特里奇亚 | 发酵的婴儿配方物 |
| CA3036494C (en) * | 2016-09-30 | 2022-10-18 | The A2 Milk Company Limited | Beta-caseins and gut microbiota |
| CN110573164B (zh) * | 2017-03-08 | 2023-09-29 | N·V·努特里奇亚 | 用于减轻鼻上皮炎症的含有不可消化的低聚糖的组合物 |
| AU2018295414A1 (en) * | 2017-07-07 | 2020-01-16 | Societe Des Produits Nestle S.A. | Human milk fortifier |
| CN107397230A (zh) * | 2017-08-21 | 2017-11-28 | 杭州特悘衡康生物科技有限公司 | 营养组合物、促进手术后肌肉恢复和蛋白质合成的配方食品及其应用 |
| US11197917B2 (en) | 2017-12-01 | 2021-12-14 | ByHeart, Inc. | Formulations for nutritional support in subjects in need thereof |
| EP3723778A1 (en) * | 2017-12-11 | 2020-10-21 | N.V. Nutricia | Composition for use for treating delayed colonization by bifidobacterium after birth |
| CN111698993A (zh) | 2018-02-09 | 2020-09-22 | N·V·努特里奇亚 | 含有不可消化寡糖的发酵配方物 |
| EP3749329A1 (en) | 2018-02-09 | 2020-12-16 | N.V. Nutricia | Fermented formula with non-digestible oligosaccharides |
| ES2940808T3 (es) | 2019-01-16 | 2023-05-11 | Nutricia Nv | Preparado fermentado con oligosacáridos no digeribles para su uso en infecciones inducidas por rotavirus |
| CN113423288A (zh) * | 2019-02-04 | 2021-09-21 | N·V·努特里奇亚 | 用于睡眠改善的含有不可消化的低聚糖的发酵配方物 |
| CN113163835A (zh) | 2019-05-15 | 2021-07-23 | N·V·努特里奇亚 | 促进肠道发育的发酵配方物 |
| US20220248739A1 (en) * | 2019-05-29 | 2022-08-11 | N.V. Nutricia | Non-digestible oligosaccharides for decreased colonic protein fermentation |
| PL3883393T3 (pl) | 2019-06-04 | 2023-01-09 | N.V. Nutricia | Kompozycja żywieniowa zawierająca 2'fukozylolaktozę i dietetyczny maślan |
| US20220110985A1 (en) | 2019-06-04 | 2022-04-14 | N.V. Nutricia | Nutritional composition comprising 2'fucosyllactose and 3'galactosyllactose |
| CN110839698A (zh) * | 2019-11-29 | 2020-02-28 | 内蒙古伊利实业集团股份有限公司 | 一种组合物及其食品用途 |
| GB2608587A (en) * | 2021-06-25 | 2023-01-11 | Mjn Us Holdings Llc | Use of extensively hydrolysed protein |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4110476A (en) | 1977-01-10 | 1978-08-29 | Johnson/Rhodes Cultured Foods, Inc. | Preparation of liquid and frozen yogurt products |
| RU2031586C1 (ru) * | 1993-02-05 | 1995-03-27 | Тамара Георгиевна Извекова | Биологически активный кисломолочный продукт "ацидолакт-наринэ" и способ его получения |
| FR2723963B1 (fr) * | 1994-08-31 | 1997-01-17 | Gervais Danone Co | Preparation de produits fermentes par streptococcus thermophilus, enrichis en galacto-oligosaccharides et en beta-galactosidase |
| EP1020123A1 (en) | 1999-01-18 | 2000-07-19 | Sitia-Yomo S.p.A. | Beverages containing live lactic bacteria |
| FR2795917B1 (fr) * | 1999-07-06 | 2001-08-31 | Gervais Danone Sa | Procede de preparation d'un produit lacte immunostimulant et ses applications |
| EP1062873A1 (en) * | 1999-12-13 | 2000-12-27 | N.V. Nutricia | Improved infant formula, protein hydrolysate for use in such an infant formula, and method for producing such a hydrolysate |
| ES2232591T3 (es) | 2000-03-01 | 2005-06-01 | Societe Des Produits Nestle S.A. | Formulacion de hidratos de carbono (adyuvante prebiotico) para la mejora de la respuesta inmune. |
| EP1145643A1 (en) | 2000-04-10 | 2001-10-17 | Phillip Connolly | Improved milk protein concentrate |
| US7431939B1 (en) | 2000-09-28 | 2008-10-07 | Mississippi State University | Inhibition of systemic infections in humans and vertebrates by dietary fibers |
| EP1364586A1 (en) * | 2002-05-24 | 2003-11-26 | Nestec S.A. | Probiotics and oral tolerance |
| RU2220579C1 (ru) * | 2002-07-31 | 2004-01-10 | Зенович Сергей Михайлович | Пищевой преимущественно кисломолочный продукт и закваска для его получения (варианты) |
| AU2003282494A1 (en) * | 2002-10-11 | 2004-05-04 | Wyeth | Nutritional formulations containing synbiotic substances |
| GB0229015D0 (en) * | 2002-12-12 | 2003-01-15 | Novartis Nutrition Ag | New Compound |
| US20050180962A1 (en) * | 2003-01-30 | 2005-08-18 | Eyal Raz | Inactivated probiotic bacteria and methods of use thereof |
| FR2853908B1 (fr) * | 2003-04-16 | 2005-06-03 | Gervais Danone Sa | Produit immunomodulateur obtenu a partir d'une culture de bifidobacterium et compositions le contenant |
| FR2857026B1 (fr) | 2003-04-16 | 2012-11-16 | Gervais Danone Sa | Produit immunomodulateur obtenu a partir d'une culture de bifidobacterium et compositions le contenant |
| PL1638416T3 (pl) | 2003-06-23 | 2013-09-30 | Nestec Sa | Zastosowanie żywnościowego preparatu do optymalizowania działania bariery jelitowej |
| EP2123282A3 (en) | 2003-10-24 | 2010-01-20 | N.V. Nutricia | Immunemodulating oligosaccharides |
| DK1675481T3 (da) * | 2003-10-24 | 2009-01-19 | Nutricia Nv | Synbiotisk præparat til börn |
| EP1597978A1 (en) | 2004-05-17 | 2005-11-23 | Nutricia N.V. | Synergism of GOS and polyfructose |
| US8252769B2 (en) | 2004-06-22 | 2012-08-28 | N. V. Nutricia | Intestinal barrier integrity |
| US7862808B2 (en) * | 2004-07-01 | 2011-01-04 | Mead Johnson Nutrition Company | Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12 |
| ES2359573T3 (es) | 2004-12-27 | 2011-05-24 | Nestec S.A. | Empleo de una fórmula para bebes con un reducido contenido en proteínas. |
| US8591981B2 (en) * | 2005-02-21 | 2013-11-26 | Nestec S.A. | Oligosaccharide mixture |
| ES2702631T5 (es) * | 2005-02-28 | 2023-03-22 | Nutricia Nv | Composición nutricional con prebióticos y probióticos |
| US7303745B2 (en) * | 2005-04-15 | 2007-12-04 | Bristol-Myers Squibb Company | Method for preventing or treating the development of respiratory allergies |
| EP1776877A1 (en) | 2005-10-21 | 2007-04-25 | N.V. Nutricia | Method for stimulating the intestinal flora |
| US20090156550A1 (en) | 2005-12-06 | 2009-06-18 | Potappel-Van T Land Belinda | Composition containing oligosaccharides for the treatment/prevention of infections |
| EP1993384A2 (en) | 2006-01-11 | 2008-11-26 | Attune Foods | Probiotic food, process for its preparation and dietary regimen |
| WO2008153377A1 (en) * | 2007-06-15 | 2008-12-18 | N.V. Nutricia | Nutrition with non-viable bifidobacterium and non-digestible oligosaccharide |
| CN102065867A (zh) | 2008-06-13 | 2011-05-18 | N.V.努特里奇亚 | 预防感染的营养物 |
| WO2010008272A1 (en) | 2008-07-15 | 2010-01-21 | N.V. Nutricia | Treatment of gut motility disorders |
| WO2010070613A2 (en) | 2008-12-18 | 2010-06-24 | University College London | Baby feeding formula and system |
| WO2012078030A1 (en) | 2010-12-06 | 2012-06-14 | N.V. Nutricia | Fermented infant formula |
| EP2520181A1 (en) | 2011-05-02 | 2012-11-07 | N.V. Nutricia | Fermented infant formula |
| BR112013013777B1 (pt) | 2010-12-06 | 2019-10-29 | Nutricia Nv | método não terapêutico e composição nutricional para bebês |
| MX2011007872A (es) | 2011-07-26 | 2013-01-29 | Nucitec Sa De Cv | Composicion nutrimental para niños que presentan reflujo, colico y/o estreñimiento. |
-
2009
- 2009-06-12 CN CN2009801222425A patent/CN102065867A/zh active Pending
- 2009-06-12 ES ES09762710.3T patent/ES2558960T3/es active Active
- 2009-06-12 WO PCT/NL2009/050330 patent/WO2009151329A1/en active Application Filing
- 2009-06-12 EP EP09762711.1A patent/EP2293677B1/en active Active
- 2009-06-12 HU HUE09762710A patent/HUE028390T2/en unknown
- 2009-06-12 BR BRPI0915149-4A patent/BRPI0915149B1/pt active IP Right Grant
- 2009-06-12 US US12/997,527 patent/US20110182934A1/en not_active Abandoned
- 2009-06-12 AR ARP090102157A patent/AR072142A1/es unknown
- 2009-06-12 AR ARP090102151A patent/AR078014A1/es unknown
- 2009-06-12 RU RU2011100828/15A patent/RU2543634C2/ru active
- 2009-06-12 EP EP09762712A patent/EP2293803A1/en not_active Ceased
- 2009-06-12 CN CN200980131512.9A patent/CN102123715B/zh active Active
- 2009-06-12 PL PL09762710T patent/PL2285387T3/pl unknown
- 2009-06-12 RU RU2011100829/10A patent/RU2498605C2/ru active
- 2009-06-12 EP EP09762710.3A patent/EP2285387B1/en active Active
- 2009-06-12 PL PL09762711T patent/PL2293677T3/pl unknown
- 2009-06-12 US US12/997,541 patent/US20110097437A1/en not_active Abandoned
- 2009-06-12 CN CN200980131387.1A patent/CN102118976B/zh active Active
- 2009-06-12 PT PT97627103T patent/PT2285387E/pt unknown
- 2009-06-12 DK DK09762710.3T patent/DK2285387T3/en active
- 2009-06-12 ES ES09762711.1T patent/ES2656776T3/es active Active
- 2009-06-12 SI SI200931354T patent/SI2285387T1/sl unknown
- 2009-06-12 US US12/997,537 patent/US20110117077A1/en not_active Abandoned
- 2009-06-12 WO PCT/NL2009/050333 patent/WO2009151331A1/en active Application Filing
- 2009-06-12 AR ARP090102156A patent/AR072141A1/es unknown
- 2009-06-12 EP EP17205129.4A patent/EP3326633A1/en not_active Withdrawn
- 2009-06-12 WO PCT/NL2009/050332 patent/WO2009151330A1/en active Application Filing
-
2016
- 2016-09-28 US US15/278,475 patent/US20170173104A1/en not_active Abandoned
-
2017
- 2017-01-13 US US15/406,361 patent/US10124016B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2558960T3 (es) | Composición nutricional para la prevención de infecciones | |
| JP5603871B2 (ja) | ホエータンパク質組成物、方法及び使用 | |
| ES2269514T3 (es) | Compuesto nutritivo para tratar afecciones inmunologicas. | |
| CN103458888A (zh) | 用于改善肠屏障功能的包含支链脂肪酸的营养组合物 | |
| MX2007010094A (es) | Mezcla de oligosacarido. | |
| CN103369975A (zh) | 具有减少的涩味的乳清蛋白组合物 | |
| CN111227045B (zh) | 乳制品在促进哺乳动物身长增长中的应用 | |
| US11116233B2 (en) | Process for producing infant formula products and acidic dairy products from milk | |
| US8921342B2 (en) | Liver function-protecting agent | |
| US20170182132A1 (en) | Use of nutritional compositions including lactoferrin in supporting resistance to diseases and conditions | |
| CN110786388A (zh) | 一种促进儿童身高发育的奶粉及其制备方法 | |
| CN102264379A (zh) | 肌肉增强剂 | |
| CN107668721A (zh) | 包含乳铁蛋白的营养组合物在支持抵抗疾病和状况中的用途 | |
| Zervas et al. | Goat milk | |
| US20120171164A1 (en) | Use of nutritional compositions including lactoferrin in supporting resistance to viral respiratory tract infections | |
| JP6330263B2 (ja) | 酸性液状食品組成物 | |
| WO2022195025A1 (en) | Liquid nutritional composition suitable for muscle function | |
| TW201242519A (en) | Flowable nutrition composition containing L-arginine and method for producing the same | |
| JP2021107400A (ja) | 肥満抑制剤 | |
| JP7300243B2 (ja) | 栄養組成物 | |
| JPH1014534A (ja) | 栄養組成物 | |
| TW201735942A (zh) | 內毒素之血中移行抑制用組成物 | |
| WO2018074415A1 (ja) | たんぱく質効率向上用の組成物 | |
| Shama | Human Milk-based Protein Concentrate Supports Growth of Weanling Rats | |
| JP2016506754A (ja) | 食品組成物及び脱水症に対するその使用 |